KOCHI: The Central Marine Fisheries Research Institute (CMFRI) has given VLCC the exclusive licence to use its recently-developed anti-obesity nutraceutical product CadalminTM Antihypercholesterolemic extract (CadalminTM ACe) for commercial production and marketing.
CMFRI director A Gopalakrishnan signed a licence agreement with VLCC Group director Sandeep Ahuja and executive vice-president (research and development) A H Zaidi. After years of intensive research, the CMFRI developed the nutraceutical product using natural marine bio-active ingredients from select seaweeds. The product was found effective in combating obesity and dyslipidemia, an abnormal amount of lipids in the blood.
Gopalakrishnan said the product provided a unique blend of 100 per cent natural marine bio-active ingredients from selected seaweeds with an eco-friendly ‘green technology’, which is under patent.
“Detailed pre-clinical trials have established the product is devoid of any side-effects even in long-term oral administration of tablets. The product is prepared from seaweeds which are known for their medicinal properties and are commonly available in the Indian coast,” he said.
“CadalminTM ACe is the fourth in the series of the nutraceutical products developed by CMFRI from seaweeds,” he said.
The CMFRI, which has already developed nutraceuticals for diabetes and arthritis, is in the process of developing more health products and nutraceuticals from seaweeds found in abundance in the country’s coastal waters,” Gopalakrishnan said.